X hits on this document

PDF document

Wan-Wan Lin1 and Michael Karin2 - page 9 / 9





9 / 9

review series

the chronic phase of colitis in IL-10–deficient mice.

      • J.

        Immunol. 161:3143–3149.

  • 102.

    Larmonier, N, et al. 2007. Tumor-derived CD4+CD25+ regulatory T cell suppression of den- dritic cell function involves TGF-beta and IL-10. Cancer Immunol. Immunother. 56:48–59.

  • 103.

    Vicari, A.P., and Trinchieri, G. 2004. Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunol. Rev. 202:223–236.

  • 104.

    Mocellin, S., Marincola, F.M., and Young, H.A.

    • 2005.

      Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol. 78:1043–1051.

  • 105.

    Kundu, N., and Fulton, A.M. 1997. Interleukin- 10 inhibits tumor metastasis, down-regulates MHC class I, and enhances NK lysis. Cell. Immunol. 180:55–61.

  • 106.

    Blankenstein, T. 2005. The role of tumor stroma in the interaction between tumor and immune system. Curr. Opin. Immunol. 17:180–186.

  • 107.

    Sredni, B., et al. 2004. Ammonium trichloro(dioxo- ethylene-o,o’)tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 64:1843–1852.

  • 108.

    Alas, S., et al. 2001. Inhibition of interleukin-10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res. 7:709–723.

  • 109.

    Ogden, C.A., et al. 2005. Enhanced apoptotic cell clearance capacity and B cell survival factor

production by IL-10–activated macrophages: implications for Burkitt’s lymphoma. J. Immunol. 174:3015–3023.

  • 110.

    Lech-Maranda, E., et al. 2006. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur. Cytokine Netw. 17:60–66.

  • 111.

    Czarneski, J, et al. 2004. Studies in NZB IL-10 knock- out mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia. 18:597–606.

  • 112.

    Garcia-Hernandez, M.L., et al. 2002. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology. 105:231–243.

  • 113.

    Chen, W.J., and Wahl, S.M. 2003. TGF-β: the miss- ing link in CD4+CD25+ regulatory T cell–mediated immunosuppression. Cytokine Growth Factor Rev. 14:85–89.

  • 114.

    Becker, C., Fantini, M.C., and Neurath, M.F. 2006. TGF-β as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev. 17:97–106.

  • 115.

    Ghiringhelli, F., et al. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-β- secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202:919–929.

  • 116.

    Derynck, R., and Zhang, Y.E. 2003. Smad-depen- dent and Smad-independent pathways in TGF-β family signaling. Nature. 425:577–584.

  • 117.

    Derynck, R., Akhurst, R.J., and Balmain, A. 2001. TGF-β signaling in tumor suppression and cancer

progression. Nat. Genet. 29:117–129.

  • 118.

    Parsons, R., et al. 1995. Microsatellite instability and mutations of the transforming growth factor type II receptor gene in colorectal cancer. Cancer Res. 55:5548–5550.

  • 119.

    Kim, S.J., Im, Y.H., Markowitz, S.D., and Bang, Y.J.

    • 2000.

      Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev. 11:159–168.

  • 120.

    Markowitz, S., et al. 1995. Inactivation of the type II TGF-β receptor in colon cancer cells with micro- satellite instability. Science. 268:1336–1338.

  • 121.

    Yang, X., et al. 1999. Targeted disruption of Smad3 results in impaired mucosal immunity and dimin- ished T cell responsiveness to TGF-β. EMBO J. 18:1280–1291.

  • 122.

    Engle, S.J., et al. 2002. Elimination of colon cancer in germ-free transforming growth factor β1–defi- cient mice. Cancer Res. 62:6362–6366.

  • 123.

    Maggio-Price, L., et al. 2006. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res. 66:828–838.

  • 124.

    Jenkins, B.J., et al. 2005. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperprolif- eration and desensitizes TGF-β signaling. Nat. Med. 11:845–852.

  • 125.

    Chen, M.L., et al. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:419–424.

The Journal of Clinical Investigation


Volume 117

Number 5

May 2007


Document info
Document views40
Page views40
Page last viewedSat Jan 21 03:13:56 UTC 2017